Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage <scp>IV</scp> Non‐Small Cell Lung Cancer With <scp>ATM</scp> Mutation: A Case Report
This case underscores the promising role of olaparib in treating NSCLC with HRD, particularly ATM mutations, highlighting the importance of molecular testing and targeted therapies.
Authors
- Ran Bi (ORCID: https://orcid.org/0000-0002-2917-7198)
- Makiko Ban‐Hoefen
- Qian Wang (ORCID: https://orcid.org/0000-0002-1201-865X)
- Zhiting Tang (ORCID: https://orcid.org/0009-0009-6479-3947)
- Qi Wang
- Mutasim Idriss
Institutions
- University of Rochester Medical Center (US)
- Inspira Medical Center Vineland (US)
- Unity Health System (US)
- University Hospitals Seidman Cancer Center (US)
- MetroHealth Medical Center (US)
- Unity Hospital (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1002/cnr2.70276
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05